Patient Selection Key to Treatment Outcomes for Antibody Drug Conjugates

Researchers at Immunogen, a maker of antibody drug conjugates (ADC) has published an article in Advances in Therapy, revealing that patient selection is vital to positive treatment outcomes. Authors Lambert and Morris are now calling for the development of an optimal patient selection strategy so that patients suffering from hard to treat cancers like mesothelioma.

Mesothelioma treatment protocols carry the potential for severe side effects because traditional chemotherapy effects both damaged and healthy cells in the body. ADC is a drug combination which can effectively target the tumor, delivering the drug with limited damage to the healthy cells.

The targeted delivery system is thought to have especially promising results with hard to treat cancers that aren’t able to be treated with normal protocols where required dosage levels beyond that which is safe. The effectiveness is based on the concentration of the target molecule in the tumor. For example mesothelin targeting ADC would be most effective in mesothelioma patients with higher levels of mesothelin.

Lambert and Morris wrote that. “The development of a patient selection strategy linked to target expression on the tumor is thus critically important for identifying the population appropriate for receiving treatment.” There are currently five different ADCs in clinical trials.

The Paul Law Firm advocates for victims of asbestos-related diseases. If you or a loved one is suffering from mesothelioma, call the Paul Law Firm. With over 2.5 billion dollars collected for victims of asbestos exposure, we have the knowledge and the experience to fight for you. We also understand that fighting doesn’t just happen in the courtroom. It also happens in a lab where we are fighting for a cure. Check out the Mesothelioma Research Foundation of America here.

Call us today at 1-855 88 LEGAL (885-3425) or contact us online to discuss your case with one of our experienced mesothelioma lawyers.